A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys.
ADP-ribosyl Cyclase 1
/ immunology
Animals
Antibodies, Monoclonal
/ immunology
Arthritis, Experimental
/ immunology
B-Lymphocytes
/ immunology
CHO Cells
Cricetulus
Disease Progression
Gene Expression Regulation
/ immunology
Killer Cells, Natural
/ immunology
Macaca fascicularis
T-Lymphocytes
/ immunology
Journal
The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
07
02
2019
accepted:
08
05
2019
pubmed:
16
5
2019
medline:
31
12
2019
entrez:
16
5
2019
Statut:
ppublish
Résumé
Ectoenzyme CD38 is increased on lymphocytes in response to an antigenic challenge and it is hypothesized that targeting these activated lymphocytes could ameliorate pathologic activities in autoimmune diseases. The cynomolgus monkey is an appropriate model for assessing potential effects of targeting CD38 in humans because these species exhibit similar expression profiles. TAK-079 is a human monoclonal antibody (IgG
Identifiants
pubmed: 31085699
pii: jpet.119.256602
doi: 10.1124/jpet.119.256602
doi:
Substances chimiques
Antibodies, Monoclonal
0
ADP-ribosyl Cyclase 1
EC 3.2.2.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
182-196Informations de copyright
Copyright © 2019 The Author(s).